46 results on '"Radmacher MD"'
Search Results
2. Molecular signatures in acute myeloid leukemia.
- Author
-
Mrózek K, Radmacher MD, Bloomfield CD, Marcucci G, Mrózek, Krzysztof, Radmacher, Michael D, Bloomfield, Clara D, and Marcucci, Guido
- Published
- 2009
- Full Text
- View/download PDF
3. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.
- Author
-
Marcucci G, Maharry K, Radmacher MD, Mrózek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus CD, Liu CG, Ruppert AS, Powell BL, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD, Marcucci, Guido, Maharry, Kati, and Radmacher, Michael D
- Published
- 2008
- Full Text
- View/download PDF
4. MicroRNA in Acute Myeloid Leukemia.
- Author
-
Ritchie WJ, Flamant S, Rasko JE, Marcucci G, Radmacher MD, and Bloomfield CD
- Published
- 2008
5. Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8.
- Author
-
Becker H, Maharry K, Mrózek K, Volinia S, Eisfeld AK, Radmacher MD, Kohlschmidt J, Metzeler KH, Schwind S, Whitman SP, Mendler JH, Wu YZ, Nicolet D, Paschka P, Powell BL, Carter TH, Wetzler M, Kolitz JE, Carroll AJ, Baer MR, Caligiuri MA, Stone RM, Marcucci G, and Bloomfield CD
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, DNA-Binding Proteins genetics, Dioxygenases, Disease-Free Survival, Female, Humans, Leukemia, Myeloid, Acute mortality, Male, Middle Aged, Prognosis, Proto-Oncogene Proteins genetics, fms-Like Tyrosine Kinase 3 genetics, Chromosomes, Human, Pair 8, Leukemia, Myeloid, Acute genetics, MicroRNAs analysis, Mutation, Trisomy
- Published
- 2014
- Full Text
- View/download PDF
6. Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study.
- Author
-
Li Z, Herold T, He C, Valk PJ, Chen P, Jurinovic V, Mansmann U, Radmacher MD, Maharry KS, Sun M, Yang X, Huang H, Jiang X, Sauerland MC, Büchner T, Hiddemann W, Elkahloun A, Neilly MB, Zhang Y, Larson RA, Le Beau MM, Caligiuri MA, Döhner K, Bullinger L, Liu PP, Delwel R, Marcucci G, Lowenberg B, Bloomfield CD, Rowley JD, Bohlander SK, and Chen J
- Subjects
- Humans, International Cooperation, Kaplan-Meier Estimate, Microarray Analysis, Middle Aged, Prognosis, Proportional Hazards Models, Gene Expression Profiling methods, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute mortality
- Abstract
Purpose: To identify a robust prognostic gene expression signature as an independent predictor of survival of patients with acute myeloid leukemia (AML) and use it to improve established risk classification., Patients and Methods: Four independent sets totaling 499 patients with AML carrying various cytogenetic and molecular abnormalities were used as training sets. Two independent patient sets composed of 825 patients were used as validation sets. Notably, patients from different sets were treated with different protocols, and their gene expression profiles were derived using different microarray platforms. Cox regression and Kaplan-Meier methods were used for survival analyses., Results: A prognostic signature composed of 24 genes was derived from a meta-analysis of Cox regression values of each gene across the four training sets. In multivariable models, a higher sum value of the 24-gene signature was an independent predictor of shorter overall (OS) and event-free survival (EFS) in both training and validation sets (P < .01). Moreover, this signature could substantially improve the European LeukemiaNet (ELN) risk classification of AML, and patients in three new risk groups classified by the integrated risk classification showed significantly (P < .001) distinct OS and EFS., Conclusion: Despite different treatment protocols applied to patients and use of different microarray platforms for expression profiling, a common prognostic gene signature was identified as an independent predictor of survival of patients with AML. The integrated risk classification incorporating this gene signature provides a better framework for risk stratification and outcome prediction than the ELN classification.
- Published
- 2013
- Full Text
- View/download PDF
7. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.
- Author
-
Mendler JH, Maharry K, Radmacher MD, Mrózek K, Becker H, Metzeler KH, Schwind S, Whitman SP, Khalife J, Kohlschmidt J, Nicolet D, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, and Bloomfield CD
- Subjects
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, DNA Mutational Analysis, Disease Progression, Disease-Free Survival, Female, Gene Expression Regulation, Neoplastic, Genetic Predisposition to Disease, Humans, Kaplan-Meier Estimate, Leukemia, Myeloid, Acute mortality, Leukemia, Myeloid, Acute pathology, Logistic Models, Male, Middle Aged, Multivariate Analysis, Nucleophosmin, Oligonucleotide Array Sequence Analysis, Phenotype, Polymerase Chain Reaction, Proportional Hazards Models, Risk Assessment, Risk Factors, Time Factors, Treatment Outcome, United States, Young Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Core Binding Factor Alpha 2 Subunit genetics, Cytogenetic Analysis, Gene Expression Profiling methods, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute genetics, MicroRNAs metabolism, Mutation
- Abstract
Purpose: To determine the association of RUNX1 mutations with therapeutic outcome in younger and older patients with primary cytogenetically normal acute myeloid leukemia (CN-AML) and with gene/microRNA expression signatures., Patients and Methods: Younger (< 60 years; n = 175) and older (≥ 60 years; n = 225) patients with CN-AML treated with intensive cytarabine/anthracycline-based first-line therapy on Cancer and Leukemia Group B protocols were centrally analyzed for RUNX1 mutations by polymerase chain reaction and direct sequencing and for established prognostic gene mutations. Gene/microRNA expression profiles were derived using microarrays., Results: RUNX1 mutations were found in 8% and 16% of younger and older patients, respectively (P = .02). They were associated with ASXL1 mutations (P < .001) and inversely associated with NPM1 (P < .001) and CEBPA (P = .06) mutations. RUNX1-mutated patients had lower complete remission rates (P = .005 in younger; P = .006 in older) and shorter disease-free survival (P = .058 in younger; P < .001 in older), overall survival (P = .003 in younger; P < .001 in older), and event-free survival (P < .001 for younger and older) than RUNX1 wild-type patients. Because RUNX1 mutations were more common in older patients and almost never coexisted with NPM1 mutations, RUNX1 mutation-associated expression signatures were derived in older, NPM1 wild-type patients and featured upregulation of genes normally expressed in primitive hematopoietic cells and B-cell progenitors, including DNTT, BAALC, BLNK, CD109, RBPMS, and FLT3, and downregulation of promoters of myelopoiesis, including CEBPA and miR-223., Conclusion: RUNX1 mutations are twice as common in older than younger patients with CN-AML and negatively impact outcome in both age groups. RUNX1-mutated blasts have molecular features of primitive hematopoietic and lymphoid progenitors, potentially leading to novel therapeutic approaches.
- Published
- 2012
- Full Text
- View/download PDF
8. miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia.
- Author
-
Eisfeld AK, Marcucci G, Maharry K, Schwind S, Radmacher MD, Nicolet D, Becker H, Mrózek K, Whitman SP, Metzeler KH, Mendler JH, Wu YZ, Liyanarachchi S, Patel R, Baer MR, Powell BL, Carter TH, Moore JO, Kolitz JE, Wetzler M, Caligiuri MA, Larson RA, Tanner SM, de la Chapelle A, and Bloomfield CD
- Subjects
- Aged, Aged, 80 and over, Cytogenetic Analysis, Disease-Free Survival, F-Box Proteins genetics, Female, Gene Expression, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Prognosis, Ubiquitin Thiolesterase genetics, Leukemia, Myeloid, Acute genetics, MicroRNAs genetics, Neoplasm Proteins genetics, RNA, Neoplasm genetics
- Abstract
High BAALC expression levels are associated with poor outcome in cytogenetically normal acute myeloid leukemia (CN-AML) patients. Recently, miR-3151 was discovered in intron 1 of BAALC. To evaluate the prognostic significance of miR-3151 expression levels and to gain insight into the biologic and prognostic interplay between miR-3151 and its host, miR-3151 and BAALC expression were measured in pretreatment blood of 179 CN-AML patients. Gene-expression profiling and miRNA-expression profiling were performed using microarrays. High miR-3151 expression was associated with shorter disease-free and overall survival, whereas high BAALC expression predicted failure of complete remission and shorter overall survival. Patients exhibiting high expression of both miR-3151 and BAALC had worse outcome than patients expressing low levels of either gene or both genes. In gene-expression profiling, high miR-3151 expressers showed down-regulation of genes involved in transcriptional regulation, posttranslational modification, and cancer pathways. Two genes, FBXL20 and USP40, were validated as direct miR-3151 targets. The results of the present study show that high expression of miR-3151 is an independent prognosticator for poor outcome in CN-AML and affects different outcome end points than its host gene, BAALC. The combination of both markers identified a patient subset with the poorest outcome. This interplay between an intronic miR and its host may have important biologic implications.
- Published
- 2012
- Full Text
- View/download PDF
9. The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia.
- Author
-
Whitman SP, Caligiuri MA, Maharry K, Radmacher MD, Kohlschmidt J, Becker H, Mrózek K, Wu YZ, Schwind S, Metzeler KH, Mendler JH, Wen J, Baer MR, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Larson RA, Marcucci G, and Bloomfield CD
- Subjects
- Adult, Aged, Cohort Studies, Cytogenetic Analysis, Female, Histone-Lysine N-Methyltransferase, Humans, Leukemia, Myeloid, Acute mortality, Male, Middle Aged, Prognosis, Survival Rate, Trisomy, Biomarkers, Tumor genetics, Leukemia, Myeloid, Acute genetics, MicroRNAs genetics, Myeloid-Lymphoid Leukemia Protein genetics, Tandem Repeat Sequences genetics
- Published
- 2012
- Full Text
- View/download PDF
10. Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia.
- Author
-
Eisfeld AK, Marcucci G, Liyanarachchi S, Döhner K, Schwind S, Maharry K, Leffel B, Döhner H, Radmacher MD, Bloomfield CD, Tanner SM, and de la Chapelle A
- Subjects
- Adult, Aged, Alleles, Binding Sites, Core Binding Factor Alpha 2 Subunit genetics, Female, Humans, Male, Middle Aged, Promoter Regions, Genetic, Leukemia, Myeloid, Acute genetics, Neoplasm Proteins genetics, Polymorphism, Single Nucleotide
- Abstract
Overexpression of the brain and acute leukemia, cytoplasmic (BAALC) gene is implicated in myeloid leukemogenesis and associated with poor outcome in both acute myeloid leukemia (AML) and acute lymphoblastic leukemia patients. Additionally, high BAALC expression occurs in glioblastoma, melanoma, and childhood gastrointestinal stroma tumors, suggesting an oncogenic role for BAALC. However, the mechanisms underlying the deregulated expression are unknown. We hypothesized that a common heritable genetic feature located in cis might account for overexpression of BAALC in an allele-specific manner. By sequencing the genomic region of BAALC we identified nine informative single nucleotide polymorphisms (SNPs) and tested them for a possible association with BAALC expression levels. We show that BAALC overexpression occurs in the presence of the T allele of SNP rs62527607[GT], which creates a binding site for the activating RUNX1 transcription factor in the BAALC promoter region. The mechanism is demonstrated experimentally in vitro using luciferase reporter assays and electrophoretic mobility shift assay (EMSA) analysis. The association of high BAALC expression with the T allele and its correlations with RUNX1 expresser status are shown in vivo in a test set (n = 253) and validation set (n = 105) of samples from cytogenetically normal AML patients from different populations. Thus, we identify a heritable genomic feature predisposing to overexpression of an oncogene, thereby possibly leading to enhanced AML leukemogenesis. Our findings further suggest that genomic variants might become useful tools in the practice of personalized medicine.
- Published
- 2012
- Full Text
- View/download PDF
11. Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML.
- Author
-
Li Z, Huang H, Li Y, Jiang X, Chen P, Arnovitz S, Radmacher MD, Maharry K, Elkahloun A, Yang X, He C, He M, Zhang Z, Dohner K, Neilly MB, Price C, Lussier YA, Zhang Y, Larson RA, Le Beau MM, Caligiuri MA, Bullinger L, Valk PJ, Delwel R, Lowenberg B, Liu PP, Marcucci G, Bloomfield CD, Rowley JD, and Chen J
- Subjects
- Acute Disease, Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Down-Regulation, Female, Gene Expression Profiling, Humans, Infant, Infant, Newborn, Kaplan-Meier Estimate, Leukemia, Myeloid pathology, Male, Middle Aged, Oligonucleotide Array Sequence Analysis, Prognosis, Up-Regulation, Young Adult, Homeodomain Proteins genetics, Leukemia, Myeloid genetics, MicroRNAs genetics, Proto-Oncogene Proteins genetics
- Abstract
Increased expression levels of miR-181 family members have been shown to be associated with favorable outcome in patients with cytogenetically normal acute myeloid leukemia. Here we show that increased expression of miR-181a and miR-181b is also significantly (P < .05; Cox regression) associated with favorable overall survival in cytogenetically abnormal AML (CA-AML) patients. We further show that up-regulation of a gene signature composed of 4 potential miR-181 targets (including HOXA7, HOXA9, HOXA11, and PBX3), associated with down-regulation of miR-181 family members, is an independent predictor of adverse overall survival on multivariable testing in analysis of 183 CA-AML patients. The independent prognostic impact of this 4-homeobox-gene signature was confirmed in a validation set of 271 CA-AML patients. Furthermore, our in vitro and in vivo studies indicated that ectopic expression of miR-181b significantly promoted apoptosis and inhibited viability/proliferation of leukemic cells and delayed leukemogenesis; such effects could be reversed by forced expression of PBX3. Thus, the up-regulation of the 4 homeobox genes resulting from the down-regulation of miR-181 family members probably contribute to the poor prognosis of patients with nonfavorable CA-AML. Restoring expression of miR-181b and/or targeting the HOXA/PBX3 pathways may provide new strategies to improve survival substantially.
- Published
- 2012
- Full Text
- View/download PDF
12. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.
- Author
-
Marcucci G, Metzeler KH, Schwind S, Becker H, Maharry K, Mrózek K, Radmacher MD, Kohlschmidt J, Nicolet D, Whitman SP, Wu YZ, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Moore JO, Caligiuri MA, Larson RA, and Bloomfield CD
- Subjects
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, DNA Methyltransferase 3A, Female, Gene Expression Profiling, Humans, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute enzymology, Male, Middle Aged, Prognosis, Young Adult, DNA (Cytosine-5-)-Methyltransferases genetics, Leukemia, Myeloid, Acute genetics, Mutation
- Abstract
Purpose: To determine the frequency of DNMT3A mutations, their associations with clinical and molecular characteristics and outcome, and the associated gene- and microRNA-expression signatures in primary cytogenetically normal acute myeloid leukemia (CN-AML)., Patients and Methods: Four hundred fifteen previously untreated adults were analyzed for DNMT3A mutations and established prognostic gene mutations and expression markers. Gene- and microRNA-expression profiles were derived using microarrays., Results: Younger (< 60 years; n = 181) and older (≥ 60 years; n = 234) patients had similar frequencies of DNMT3A mutations (35.3% v 33.3%). Missense mutations affecting arginine codon 882 (R882-DNMT3A) were more common (n = 92; 62%) than those affecting other codons (non-R882-DNMT3A). DNMT3A-mutated patients did not differ regarding complete remission rate, but had shorter disease-free survival (DFS; P = .03) and, by trend, overall survival (OS; P = .07) than DNMT3A-wild-type patients. In multivariable analyses, DNMT3A mutations remained associated with shorter DFS (P = .01), but not with shorter OS. When analyzed separately, the two DNMT3A mutation types had different significance by age group. Younger patients with non-R882-DNMT3A mutations had shorter DFS (P = .002) and OS (P = .02), whereas older patients with R882-DNMT3A mutations had shorter DFS (P = .005) and OS (P = .002) after adjustment for other clinical and molecular prognosticators. Gene- and microRNA-expression signatures did not accurately predict DNMT3A mutational status., Conclusion: DNMT3A mutations are frequent in CN-AML, and their clinical significance seems to be age dependent. DNMT3A-R882 mutations are associated with adverse prognosis in older patients, and non-R882-DNMT3A mutations are associated with adverse prognosis in younger patients. Low accuracy of gene- and microRNA-expression signatures in predicting DNMT3A mutation status suggested that the role of these mutations in AML remains to be elucidated.
- Published
- 2012
- Full Text
- View/download PDF
13. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.
- Author
-
Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Mrózek K, Nicolet D, Whitman SP, Wu YZ, Schwind S, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, and Bloomfield CD
- Subjects
- Acute Disease, Age Factors, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols therapeutic use, CCAAT-Enhancer-Binding Proteins genetics, Exons genetics, Female, Humans, Kaplan-Meier Estimate, Leukemia, Myeloid drug therapy, Leukemia, Myeloid pathology, Male, MicroRNAs genetics, Middle Aged, Multivariate Analysis, Nucleophosmin, Oligonucleotide Array Sequence Analysis, Prognosis, Risk Factors, Treatment Outcome, Gene Expression Profiling, Leukemia, Myeloid genetics, Mutation, Repressor Proteins genetics
- Abstract
The associations of mutations in the enhancer of trithorax and polycomb family gene ASXL1 with pretreatment patient characteristics, outcomes, and gene-/microRNA-expression profiles in primary cytogenetically normal acute myeloid leukemia (CN-AML) are unknown. We analyzed 423 adult patients for ASXL1 mutations, other prognostic gene mutations, and gene-/microRNA-expression profiles. ASXL1 mutations were 5 times more common in older (≥ 60 years) patients (16.2%) than those younger than 60 years (3.2%; P < .001). Among older patients, ASXL1 mutations associated with wild-type NPM1 (P < .001), absence of FLT3-internal tandem duplications (P = .002), mutated CEBPA (P = .01), and with inferior complete remission (CR) rate (P = .04), disease-free survival (DFS; P = .03), overall survival (OS; P = .006), and event-free survival (EFS; P = .002). Within the European LeukemiaNet (ELN) genetic categories of older CN-AML, ASXL1 mutations associated with inferior CR rate (P = .02), OS (P < .001), and EFS (P < .001) among ELN Favorable, but not among ELN Intermediate-I patients. Multivariable analyses confirmed associations of ASXL1 mutations with unfavorable CR rate (P = .03), DFS (P < .001), OS (P < .001), and EFS (P < .001) among ELN Favorable patients. We identified an ASXL1 mutation-associated gene-expression signature, but no microRNA-expression signature. This first study of ASXL1 mutations in primary CN-AML demonstrates that ASXL1-mutated older patients, particularly within the ELN Favorable group, have unfavorable outcomes and may be candidates for experimental treatment approaches.
- Published
- 2011
- Full Text
- View/download PDF
14. Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia.
- Author
-
Schwind S, Marcucci G, Kohlschmidt J, Radmacher MD, Mrózek K, Maharry K, Becker H, Metzeler KH, Whitman SP, Wu YZ, Powell BL, Baer MR, Kolitz JE, Carroll AJ, Larson RA, Caligiuri MA, and Bloomfield CD
- Subjects
- Adult, Aged, Female, Humans, Leukemia, Myeloid, Acute mortality, Leukemia, Myeloid, Acute therapy, Male, Middle Aged, Nucleophosmin, Predictive Value of Tests, Survival Rate, Trans-Activators, Biomarkers, Tumor biosynthesis, Gene Expression Regulation, Leukemic, Leukemia, Myeloid, Acute metabolism, Tumor Suppressor Proteins biosynthesis
- Abstract
Low MN1 expression bestows favorable prognosis in younger adults with cytogenetically normal acute myeloid leukemia (CN-AML), but its prognostic significance in older patients is unknown. We analyzed pretherapy MN1 expression in 140 older (≥ 60 years) de novo CN-AML patients treated on cytarabine/daunorubicin-based protocols. Low MN1 expressers had higher complete remission (CR) rates (P = .001), and longer overall survival (P = .03) and event-free survival (EFS; P = .004). In multivariable models, low MN1 expression was associated with better CR rates and EFS. The impact of MN1 expression on overall survival and EFS was predominantly in patients 70 years of age or older, with low MN1 expressers with mutated NPM1 having the best outcome. The impact of MN1 expression was also observed in the Intermediate-I, but not the Favorable group of the European LeukemiaNet classification, where low MN1 expressers had CR rates and EFS similar to those of Favorable group patients. MN1 expresser-status-associated gene- and microRNA-expression signatures revealed underexpression of drug resistance and adverse outcome predictors, and overexpression of HOX genes and HOX-gene-embedded microRNAs in low MN1 expressers. We conclude that low MN1 expression confers better prognosis in older CN-AML patients and may refine the European LeukemiaNet classification. Biologic features associated with MN1 expression may help identify new treatment targets.
- Published
- 2011
- Full Text
- View/download PDF
15. Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
- Author
-
Becker H, Maharry K, Radmacher MD, Mrózek K, Metzeler KH, Whitman SP, Schwind S, Kohlschmidt J, Wu YZ, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Moore JO, Caligiuri MA, Larson RA, Marcucci G, and Bloomfield CD
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Alleles, Female, Gene Expression Regulation, Leukemic, Gene Frequency, Genotype, Humans, Male, Middle Aged, Nucleophosmin, Prognosis, Young Adult, Gene Expression Profiling, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute mortality, MicroRNAs metabolism, Polymorphism, Single Nucleotide, WT1 Proteins genetics
- Abstract
Background: The alleles of the Wilms tumor 1 (WT1) polymorphism rs16754 harbor adenine (A) or guanine (G). Recently, rs16754 has been reported to affect the outcome of patients with cytogenetically normal acute myeloid leukemia. To validate this finding, we investigated pretreatment features and outcome associated with rs16754 in a large cohort of patients with cytogenetically normal acute myeloid leukemia., Design and Methods: Four-hundred and thirty-three intensively treated and molecularly characterized cytogenetically normal patients with de novo acute myeloid leukemia (18-83 years old) were analyzed for rs16754. To gain biological insights, we studied the gene- and microRNA-expression profiles for associations with rs16754., Results: Three-hundred and nine (71%) patients were homozygous for A (WT1(AA)), 112 (26%) were heterozygous (WT1(AG)) and 12 (3%) were homozygous for G (WT1(GG)). For comparison with previous studies, we grouped WT1(AG) and WT1(GG) patients and compared them with WT1(AA) patients divided into younger (<60 years) and older (≥60 years) adults. We found no independent prognostic impact of WT1(AA). However, WT1(GG) patients, who were less often Caucasian than WT1(AG) (P=0.001) or WT1(AA) (P=0.008) patients, and had TET2 mutations more often than WT1(AG) (P=0.02) patients, had, among patients with FLT3-internal tandem duplication and/or NPM1 wild-type, better disease-free (P=0.02) and overall survival (P=0.04) than WT1(AA) and WT1(AG) patients combined. Unsupervised and supervised analyses of the gene- and microRNA-expression profiles suggested that there were no distinct expression patterns associated with any rs16754 genotype., Conclusions: We did not observe the previously reported adverse impact of WT1(AA) but found favorable outcomes associated with the homozygous WT1(GG). Considering its low frequency, confirmatory studies are necessary. The biological significance of rs16754 remains questionable as no distinct expression profiles were associated with the genotypes.
- Published
- 2011
- Full Text
- View/download PDF
16. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
- Author
-
Metzeler KH, Maharry K, Radmacher MD, Mrózek K, Margeson D, Becker H, Curfman J, Holland KB, Schwind S, Whitman SP, Wu YZ, Blum W, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, and Bloomfield CD
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cytogenetic Analysis, DNA Mutational Analysis, Dioxygenases, Disease-Free Survival, Female, Gene Expression Profiling, Gene Expression Regulation, Leukemic, Genetic Predisposition to Disease, Humans, Kaplan-Meier Estimate, Leukemia, Myeloid, Acute classification, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute mortality, Male, MicroRNAs analysis, Middle Aged, Nucleophosmin, Phenotype, Polymerase Chain Reaction, Proportional Hazards Models, Risk Assessment, Risk Factors, Time Factors, Treatment Outcome, United States, Young Adult, DNA-Binding Proteins genetics, Leukemia, Myeloid, Acute genetics, Mutation, Proto-Oncogene Proteins genetics
- Abstract
Purpose: To determine the frequency of TET2 mutations, their associations with clinical and molecular characteristics and outcome, and the associated gene- and microRNA-expression signatures in patients with primary cytogenetically normal acute myeloid leukemia (CN-AML)., Patients and Methods: Four-hundred twenty-seven patients with CN-AML were analyzed for TET2 mutations by polymerase chain reaction and direct sequencing and for established prognostic gene mutations. Gene- and microRNA-expression profiles were derived using microarrays., Results: TET2 mutations, found in 23% of patients, were associated with older age (P < .001) and higher pretreatment WBC (P = .04) compared with wild-type TET2 (TET2-wt). In the European LeukemiaNet (ELN) favorable-risk group (patients with CN-AML who have mutated CEBPA and/or mutated NPM1 without FLT3 internal tandem duplication [FLT3-ITD]), TET2-mutated patients had shorter event-free survival (EFS; P < .001) because of a lower complete remission (CR) rate (P = .007), and shorter disease-free survival (DFS; P = .003), and also had shorter overall survival (P = .001) compared with TET2-wt patients. TET2 mutations were not associated with outcomes in the ELN intermediate-I-risk group (CN-AML with wild-type CEBPA and wild-type NPM1 and/or FLT3-ITD). In multivariable models, TET2 mutations were associated with shorter EFS (P = .004), lower CR rate (P = .03), and shorter DFS (P = .05) only among favorable-risk CN-AML patients. We identified a TET2 mutation-associated gene-expression signature in favorable-risk but not in intermediate-I-risk patients and found distinct mutation-associated microRNA signatures in both ELN groups., Conclusion: TET2 mutations improve the ELN molecular-risk classification in primary CN-AML because of their adverse prognostic impact in an otherwise favorable-risk patient subset. Our data suggest that these patients may be candidates for alternative therapies.
- Published
- 2011
- Full Text
- View/download PDF
17. The prognostic and functional role of microRNAs in acute myeloid leukemia.
- Author
-
Marcucci G, Mrózek K, Radmacher MD, Garzon R, and Bloomfield CD
- Subjects
- Cytogenetic Analysis, Gene Expression Profiling, Gene Expression Regulation, Leukemic, Humans, Leukemia, Myeloid, Acute pathology, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute genetics, MicroRNAs genetics, MicroRNAs physiology
- Abstract
Expression of microRNAs, a new class of noncoding RNAs that hybridize to target messenger RNA and regulate their translation into proteins, has been recently demonstrated to be altered in acute myeloid leukemia (AML). Distinctive patterns of increased expression and/or silencing of multiple microRNAs (microRNA signatures) have been associated with specific cytogenetic and molecular subsets of AML. Changes in the expression of several microRNAs altered in AML have been shown to have functional relevance in leukemogenesis, with some microRNAs acting as oncogenes and others as tumor suppressors. Both microRNA signatures and a single microRNA (ie, miR-181a) have been shown to supply prognostic information complementing that gained from cytogenetics, gene mutations, and altered gene expression. Moreover, it has been demonstrated experimentally that antileukemic effects can be achieved by modulating microRNA expression by pharmacologic agents and/or increasing low endogenous levels of microRNAs with tumor suppressor function by synthetic microRNA oligonucleotides, or down-regulating high endogenous levels of leukemogenic microRNAs by antisense oligonucleotides (antagomirs). Therefore, it is reasonable to predict the development of novel microRNA-based therapeutic approaches in AML. We review herein results of current studies analyzing changes of microRNA expression in AML and discuss their potential biologic, diagnostic, and prognostic relevance.
- Published
- 2011
- Full Text
- View/download PDF
18. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
- Author
-
Schwind S, Maharry K, Radmacher MD, Mrózek K, Holland KB, Margeson D, Whitman SP, Hickey C, Becker H, Metzeler KH, Paschka P, Baldus CD, Liu S, Garzon R, Powell BL, Kolitz JE, Carroll AJ, Caligiuri MA, Larson RA, Marcucci G, and Bloomfield CD
- Subjects
- Adolescent, Adult, Gene Expression Profiling, Humans, Middle Aged, Nucleophosmin, Oligonucleotide Array Sequence Analysis, Prognosis, Young Adult, Leukemia, Myeloid, Acute genetics, MicroRNAs genetics
- Abstract
Purpose: To evaluate the prognostic significance of expression levels of a single microRNA, miR-181a, in the context of established molecular markers in cytogenetically normal acute myeloid leukemia (CN-AML), and to gain insight into the leukemogenic role of miR-181a., Patients and Methods: miR-181a expression was measured in pretreatment marrow using Ohio State University Comprehensive Cancer Center version 3.0 arrays in 187 younger (<60 years) adults with CN-AML. Presence of other molecular prognosticators was assessed centrally. A gene-expression profile associated with miR-181a expression was derived using microarrays and evaluated by Gene-Ontology analysis., Results: Higher miR-181a expression associated with a higher complete remission (CR) rate (P=.04), longer overall survival (OS; P=.01) and a trend for longer disease-free survival (DFS; P=.09). The impact of miR-181a was most striking in poor molecular risk patients with FLT3-internal tandem duplication (FLT3-ITD) and/or NPM1 wild-type, where higher miR-181a expression associated with a higher CR rate (P=.009), and longer DFS (P<.001) and OS (P<.001). In multivariable analyses, higher miR-181a expression was significantly associated with better outcome, both in the whole patient cohort and in patients with FLT3-ITD and/or NPM1 wild-type. These results were also validated in an independent set of older (≥60 years) patients with CN-AML. A miR-181a-associated gene-expression profile was characterized by enrichment of genes usually involved in innate immunity., Conclusion: To our knowledge, we provide the first evidence that the expression of a single microRNA, miR-181a, is associated with clinical outcome of patients with CN-AML and may refine their molecular risk classification. Targeted treatments that increase endogenous levels of miR-181a might represent novel therapeutic strategies.
- Published
- 2010
- Full Text
- View/download PDF
19. BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
- Author
-
Schwind S, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Holland KB, Margeson D, Becker H, Whitman SP, Wu YZ, Metzeler KH, Powell BL, Kolitz JE, Carter TH, Moore JO, Baer MR, Carroll AJ, Caligiuri MA, Larson RA, and Bloomfield CD
- Subjects
- Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cytarabine administration & dosage, Cytogenetic Analysis, Daunorubicin administration & dosage, Female, Humans, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute pathology, Male, Middle Aged, Oligonucleotide Array Sequence Analysis, RNA, Messenger genetics, Reverse Transcriptase Polymerase Chain Reaction, Survival Rate, Transcriptional Regulator ERG, Treatment Outcome, Biomarkers, Tumor genetics, Gene Expression Profiling, Leukemia, Myeloid, Acute genetics, MicroRNAs genetics, Neoplasm Proteins genetics, Trans-Activators genetics
- Abstract
BAALC and ERG expression levels are prognostic markers in younger (< 60 years) cytogenetically normal acute myeloid leukemia (CN-AML) adults; their prognostic impact in older (≥ 60 years) patients requires further investigation. We evaluated pretreatment expression of BAALC and ERG in 158 de novo patients treated on cytarabine/daunorubicin-based protocols. The patients were also characterized for other established molecular prognosticators. Low BAALC and ERG expression levels were associated with better outcome in univariable and multivariable analyses. Expression levels of both BAALC and ERG were the only factors significantly associated with overall survival upon multivariable analysis. To gain biological insights, we derived gene expression signatures associated with BAALC and ERG expression in older CN-AML patients. Furthermore, we derived the first microRNA expression signatures associated with the expression of these 2 genes. In low BAALC expressers, genes associated with undifferentiated hematopoietic precursors and unfavorable outcome predictors were down-regulated, whereas HOX genes and HOX-gene-embedded microRNAs were up-regulated. Low ERG expressers presented with down-regulation of genes involved in the DNA-methylation machinery, and up-regulation of miR-148a, which targets DNMT3B. We conclude that in older CN-AML patients, low BAALC and ERG expression associates with better outcome and distinct gene and microRNA expression signatures that could aid in identifying new targets and novel therapeutic strategies for older patients.
- Published
- 2010
- Full Text
- View/download PDF
20. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
- Author
-
Whitman SP, Maharry K, Radmacher MD, Becker H, Mrózek K, Margeson D, Holland KB, Wu YZ, Schwind S, Metzeler KH, Wen J, Baer MR, Powell BL, Carter TH, Kolitz JE, Wetzler M, Moore JO, Stone RM, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, and Bloomfield CD
- Subjects
- Age Factors, Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cytogenetics, Female, Gene Expression Regulation, Leukemic, Humans, Leukemia, Myeloid, Acute drug therapy, Male, MicroRNAs genetics, Middle Aged, Prognosis, Survival Analysis, Gene Duplication, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute genetics, fms-Like Tyrosine Kinase 3 genetics
- Abstract
The clinical impact of FLT3-internal tandem duplications (ITDs), an adverse prognostic marker in adults aged < 60 years with primary cytogenetically normal acute myeloid leukemia (CN-AML), requires further investigation in older patients. In CN-AML patients aged ≥ 60 years treated on Cancer and Leukemia Group B frontline trials, we found that FLT3-ITD remained associated with shorter disease-free survival (P < .001; hazard ratio = 2.10) and overall survival (P < .001; hazard ratio = 1.97) in multivariable analyses. This impact on shorter disease-free survival and overall survival was in patients aged 60-69 (P < .001, each) rather than in those aged ≥ 70 years. An FLT3-ITD-associated gene-expression signature revealed overexpression of FLT3, homeobox genes (MEIS1, PBX3, HOXB3), and immunotherapeutic tar-gets (WT1, CD33) and underexpression of leukemia-associated (MLLT3, TAL1) and erythropoiesis-associated (GATA3, EPOR, ANK1, HEMGN) genes. An FLT3-ITD-associated microRNA-expression signature included overexpressed miR-155 and underexpressed miR-144 and miR-451. FLT3-ITD identifies older CN-AML patients with molecular high risk and is associated with gene- and microRNA-expression signatures that provide biologic insights for novel therapeutic approaches.
- Published
- 2010
- Full Text
- View/download PDF
21. Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
- Author
-
Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, Whitman SP, Paschka P, Holland KB, Schwind S, Wu YZ, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Moore JO, Caligiuri MA, Larson RA, and Bloomfield CD
- Subjects
- Acute Disease, Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Cohort Studies, DNA Mutational Analysis, Female, Homeostasis genetics, Humans, Kaplan-Meier Estimate, Leukemia, Myeloid mortality, Male, Middle Aged, Neoplasm Proteins biosynthesis, Neoplasm Proteins genetics, Prognosis, Survival Analysis, Treatment Outcome, Young Adult, Gene Expression Profiling, Gene Expression Regulation, Leukemic, Genes, Wilms Tumor, Leukemia, Myeloid genetics
- Abstract
We previously reported the adverse prognostic impact of Wilms tumor 1 gene (WT1) mutations in younger adult cytogenetically normal acute myeloid leukemia (CN-AML). Here, we investigated 243 older (> or = 60 years) primary CN-AML patients. WT1 mutated (WT1mut) patients (7%) had FLT3-ITD more frequently (P < .001), lower hemoglobin (P = .01), higher white blood cell count (P = .03) and percentage blood blasts (P = .03), and a shorter overall survival (P = .08) than WT1 wild-type (WT1wt) patients. Comparing older and younger WT1mut patients, they had similar pretreatment characteristics and outcome. By contrast, among WT1wt CN-AML, younger patients had a significantly better outcome. A WT1 mutation-associated gene-expression signature, reported here for the first time, included CD96, a leukemia stem cell-specific marker, and genes involved in gene regulation (eg, MLL, PML, and SNRPN) and in proliferative and metabolic processes (eg, INSR, IRS2, and PRKAA1), supporting the role of mutated WT1 in deregulating multiple homeostatic processes. Our results indicate that WT1mut CN-AML represents a distinct entity with poor treatment response across age groups. This study has been registered at www.clinicaltrials.gov as #NCT00900224.
- Published
- 2010
- Full Text
- View/download PDF
22. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
- Author
-
Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrózek K, Margeson D, Holland KB, Whitman SP, Becker H, Schwind S, Metzeler KH, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, and Bloomfield CD
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols therapeutic use, DNA Mutational Analysis, Disease-Free Survival, Female, Gene Expression Profiling, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Leukemic, Gene Frequency, Genotype, Humans, Kaplan-Meier Estimate, Karyotyping, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute mortality, Male, MicroRNAs analysis, Middle Aged, Nucleophosmin, Phenotype, Recurrence, Risk Assessment, Risk Factors, Time Factors, Treatment Outcome, Young Adult, Isocitrate Dehydrogenase genetics, Leukemia, Myeloid, Acute genetics, Mutation
- Abstract
PURPOSE To analyze the frequency and associations with prognostic markers and outcome of mutations in IDH genes encoding isocitrate dehydrogenases in adult de novo cytogenetically normal acute myeloid leukemia (CN-AML). PATIENTS AND METHODS Diagnostic bone marrow or blood samples from 358 patients were analyzed for IDH1 and IDH2 mutations by DNA polymerase chain reaction amplification/sequencing. FLT3, NPM1, CEBPA, WT1, and MLL mutational analyses and gene- and microRNA-expression profiling were performed centrally. Results IDH mutations were found in 33% of the patients. IDH1 mutations were detected in 49 patients (14%; 47 with R132). IDH2 mutations, previously unreported in AML, were detected in 69 patients (19%; 13 with R172 and 56 with R140). R172 IDH2 mutations were mutually exclusive with all other prognostic mutations analyzed. Younger age (< 60 years), molecular low-risk (NPM1-mutated/FLT3-internal tandem duplication-negative) IDH1-mutated patients had shorter disease-free survival than molecular low-risk IDH1/IDH2-wild-type (wt) patients (P = .046). R172 IDH2-mutated patients had lower complete remission rates than IDH1/IDH2wt patients (P = .007). Distinctive microarray gene- and microRNA-expression profiles accurately predicted R172 IDH2 mutations. The highest expressed gene and microRNAs in R172 IDH2-mutated patients compared with the IDH1/IDH2wt patients were APP (previously associated with complex karyotype AML) and miR-1 and miR-133 (involved in embryonal stem-cell differentiation), respectively. CONCLUSION IDH1 and IDH2 mutations are recurrent in CN-AML and have an unfavorable impact on outcome. The R172 IDH2 mutations, previously unreported in AML, characterize a novel subset of CN-AML patients lacking other prognostic mutations and associate with unique gene- and microRNA-expression profiles that may lead to the discovery of novel, therapeutically targetable leukemogenic mechanisms.
- Published
- 2010
- Full Text
- View/download PDF
23. Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia.
- Author
-
Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu YZ, Hickey CJ, Yu J, Becker H, Maharry K, Radmacher MD, Li C, Whitman SP, Mishra A, Stauffer N, Eiring AM, Briesewitz R, Baiocchi RA, Chan KK, Paschka P, Caligiuri MA, Byrd JC, Croce CM, Bloomfield CD, Perrotti D, Garzon R, and Marcucci G
- Subjects
- Cell Line, Tumor, Chromosomes, Human, Pair 7 genetics, Gene Expression Regulation, Neoplastic, Genetic Vectors, Homeostasis, Humans, Leukemia, Myeloid physiopathology, Transcription, Genetic, Histone Deacetylases physiology, Immunoglobulins physiology, Leukemia, Myeloid genetics, MicroRNAs physiology, NF-kappa B physiology, Proto-Oncogene Proteins c-kit genetics
- Abstract
The biologic and clinical significance of KIT overexpression that associates with KIT gain-of-function mutations occurring in subsets of acute myeloid leukemia (AML) (i.e., core binding factor AML) is unknown. Here, we show that KIT mutations lead to MYC-dependent miR-29b repression and increased levels of the miR-29b target Sp1 in KIT-driven leukemia. Sp1 enhances its own expression by participating in a NFkappaB/HDAC complex that further represses miR-29b transcription. Upregulated Sp1 then binds NFkappaB and transactivates KIT. Therefore, activated KIT ultimately induces its own transcription. Our results provide evidence that the mechanisms of Sp1/NFkappaB/HDAC/miR-29b-dependent KIT overexpression contribute to leukemia growth and can be successfully targeted by pharmacological disruption of the Sp1/NFkappaB/HDAC complex or synthetic miR-29b treatment in KIT-driven AML., (Copyright 2010 Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
24. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.
- Author
-
Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, Whitman SP, Wu YZ, Schwind S, Paschka P, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, and Bloomfield CD
- Subjects
- Aged, Aged, 80 and over, CCAAT-Enhancer-Binding Proteins genetics, Female, Gene Expression Profiling, Gene Expression Regulation, Leukemic, Humans, Karyotyping, Leukemia, Myeloid, Acute pathology, Leukemia, Myeloid, Acute therapy, Male, Middle Aged, Neoplasm Staging, Nucleophosmin, Oligonucleotide Array Sequence Analysis, Prognosis, Remission Induction, Survival Rate, Treatment Outcome, WT1 Proteins genetics, fms-Like Tyrosine Kinase 3 genetics, Biomarkers, Tumor genetics, Leukemia, Myeloid, Acute genetics, MicroRNAs physiology, Mutation genetics, Nuclear Proteins genetics
- Abstract
Purpose: To analyze the prognostic significance of NPM1 mutations, and the associated gene- and microRNA-expression signatures in older patients with de novo, cytogenetically normal acute myeloid leukemia (CN-AML) treated with intensive chemotherapy., Patients and Methods: One hundred forty-eight adults age >or= 60 years with de novo CN-AML, enrolled onto Cancer and Leukemia Group B protocols 9720 and 10201, were studied at diagnosis for NPM1, FLT3, CEBPA, and WT1 mutations, and gene- and microRNA-expression profiles., Results: Patients with NPM1 mutations (56%) had higher complete remission (CR) rates (84% v 48%; P < .001) and longer disease-free survival (DFS; P = .047; 3-year rates, 23% v 10%) and overall survival (OS; P < .001; 3-year rates, 35% v 8%) than NPM1 wild-type patients. In multivariable analyses, NPM1 mutations remained independent predictors for higher CR rates (P < .001) and longer DFS (P = .004) and OS (P < .001), after adjustment for other prognostic clinical and molecular variables. Unexpectedly, the prognostic impact of NPM1 mutations was mainly observed in patients >or= 70 years. Gene- and microRNA-expression profiles associated with NPM1 mutations were similar across older patient age groups and similar to those in younger (< 60 years) patients with CN-AML. These profiles were characterized by upregulation of HOX genes and their embedded microRNAs and downregulation of the prognostically adverse MN1, BAALC, and ERG genes., Conclusion: NPM1 mutations have favorable prognostic impact in older patients with CN-AML, especially those age >or= 70 years. The gene- and microRNA-expression profiles suggest that NPM1 mutations constitute a marker defining a biologically homogeneous entity in CN-AML that might be treated with specific and/or targeted therapies across age groups.
- Published
- 2010
- Full Text
- View/download PDF
25. MicroRNA expression profiling in acute myeloid and chronic lymphocytic leukaemias.
- Author
-
Marcucci G, Mrózek K, Radmacher MD, Bloomfield CD, and Croce CM
- Subjects
- Female, Humans, Leukemia, Lymphocytic, Chronic, B-Cell genetics, Male, Middle Aged, Oligonucleotide Array Sequence Analysis, Prognosis, Up-Regulation, Gene Expression Profiling methods, Leukemia, Myeloid, Acute genetics, MicroRNAs genetics
- Abstract
Altered expression of microRNAs, a new class of noncoding RNAs that regulate messenger RNA and protein expression of target genes, has been recently demonstrated to have an essential role in the process of leukaemogenesis. Distinctive patterns of activation and/or silencing of multiple microRNAs (microRNA signatures) associated with certain cytogenetic and molecular subsets of leukaemia have been identified using genome-wide high-throughput profiling assays. This has led not only to the discovery of new molecular pathways implicated in leukaemogenesis, but also supplied prognostic information complementing that gained from cytogenetics, gene mutations and altered gene expression in acute and chronic leukaemias. We review herein results of current studies analysing changes of microRNA expression in acute myeloid leukaemia and chronic lymphocytic leukaemia, and discuss their potential biologic, diagnostic and prognostic relevance.
- Published
- 2009
- Full Text
- View/download PDF
26. MicroRNA expression in acute myeloid leukemia.
- Author
-
Marcucci G, Radmacher MD, Mrózek K, and Bloomfield CD
- Subjects
- Genetic Predisposition to Disease, Genome-Wide Association Study, Humans, Leukemia, Myeloid pathology, Leukemia, Myeloid therapy, Prognosis, Gene Expression Profiling, Gene Expression Regulation, Leukemic, Leukemia, Myeloid genetics, MicroRNAs genetics
- Abstract
Acute myeloid leukemia (AML) is a group of diseases that are very heterogeneous with regard to cytogenetic aberrations, gene mutations, and changes in expression of numerous genes. A new class of genes known as microRNAs recently was found to be involved in myeloid leukemogenesis. These genes are transcribed into regulatory, noncoding RNAs that control mRNA and protein expression of target genes. Genome-wide analyses of microRNA expression have revealed signatures associated with selected cytogenetic and molecular subsets of AML and have led to the recognition of previously unreported molecular pathways involved in myeloid leukemogenesis. In cytogenetically normal AML, microRNA-expression profiling has also provided prognostic information in addition to that obtained from cytogenetics and analyses of gene mutations and aberrant gene expression. This article reviews recent studies that were focused on the alterations of microRNA expression in AML and their diagnostic and prognostic significance.
- Published
- 2009
- Full Text
- View/download PDF
27. Gene expression profiling reveals similarities between the in vitro and in vivo responses of immune effector cells to IFN-alpha.
- Author
-
Zimmerer JM, Lesinski GB, Ruppert AS, Radmacher MD, Noble C, Kendra K, Walker MJ, and Carson WE 3rd
- Subjects
- Blood Donors, Female, Gene Expression Profiling, Humans, Interferon alpha-2, Interferon-alpha therapeutic use, Killer Cells, Natural immunology, Male, Melanoma drug therapy, Microarray Analysis, Monocytes immunology, Recombinant Proteins, T-Lymphocytes immunology, Transcriptional Activation, Up-Regulation, Interferon-alpha pharmacology, Leukocytes, Mononuclear immunology, Melanoma immunology
- Abstract
Purpose: The precise molecular targets of IFN-alpha therapy in the context of malignant melanoma are unknown but seem to involve signal transducers and activators of transcription 1 signal transduction within host immune effector cells. We hypothesized that the in vitro transcriptional response of patient peripheral blood mononuclear cells (PBMC) to IFN-alpha would be similar to the in vivo response to treatment with high-dose IFN-alpha., Experimental Design: The gene expression profiles of PBMCs and immune cell subsets treated in vitro with IFN-alpha were evaluated, as were PBMCs obtained from melanoma patients receiving adjuvant IFN-alpha., Results: Twenty-seven genes were up-regulated in PBMCs from normal donors after treatment with IFN-alpha in vitro for 18 hours (>2-fold, P < 0.001). A subset of these genes (in addition to others) was significantly expressed in IFN-alpha-treated T cells, natural killer cells, and monocytes. Analysis of gene expression within PBMCs from melanoma patients (n = 13) receiving high-dose IFN-alpha-2b (20 MU/m(2) i.v.) revealed significant up-regulation (>2-fold) of 21 genes (P < 0.001). Also, the gene expression profile of in vitro IFN-alpha-stimulated patient PBMCs was similar to that of PBMCs obtained from the same patient after IFN-alpha therapy., Conclusions: This report is the first to describe the transcriptional response of T cells, natural killer cells, and monocytes to IFN-alpha and characterize the transcriptional profiles of PBMCs from melanoma patients undergoing IFN-alpha immunotherapy. In addition, it was determined that microarray analysis of patient PBMCs after in vitro stimulation with IFN-alpha may be a useful predictor of the in vivo response of immune cells to IFN-alpha immunotherapy.
- Published
- 2008
- Full Text
- View/download PDF
28. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study.
- Author
-
Langer C, Radmacher MD, Ruppert AS, Whitman SP, Paschka P, Mrózek K, Baldus CD, Vukosavljevic T, Liu CG, Ross ME, Powell BL, de la Chapelle A, Kolitz JE, Larson RA, Marcucci G, and Bloomfield CD
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Gene Expression Profiling, Humans, Kaplan-Meier Estimate, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute mortality, Nucleophosmin, Oligonucleotide Array Sequence Analysis, Prognosis, RNA, Messenger analysis, Reverse Transcriptase Polymerase Chain Reaction, Treatment Outcome, Biomarkers, Tumor analysis, Gene Expression, Leukemia, Myeloid, Acute metabolism, Neoplasm Proteins biosynthesis
- Abstract
BAALC expression is considered an independent prognostic factor in cytogenetically normal acute myeloid leukemia (CN-AML), but has yet to be investigated together with multiple other established prognostic molecular markers in CN-AML. We analyzed BAALC expression in 172 primary CN-AML patients younger than 60 years of age, treated similarly on CALGB protocols. High BAALC expression was associated with FLT3-ITD (P = .04), wild-type NPM1 (P < .001), mutated CEBPA (P = .003), MLL-PTD (P = .009), absent FLT3-TKD (P = .005), and high ERG expression (P = .05). In multivariable analysis, high BAALC expression independently predicted lower complete remission rates (P = .04) when adjusting for ERG expression and age, and shorter survival (P = .04) when adjusting for FLT3-ITD, NPM1, CEBPA, and white blood cell count. A gene-expression signature of 312 probe sets differentiating high from low BAALC expressers was identified. High BAALC expression was associated with overexpression of genes involved in drug resistance (MDR1) and stem cell markers (CD133, CD34, KIT). Global microRNA-expression analysis did not reveal significant differences between BAALC expression groups. However, an analysis of microRNAs that putatively target BAALC revealed a potentially interesting inverse association between expression of miR-148a and BAALC. We conclude that high BAALC expression is an independent adverse prognostic factor and is associated with a specific gene-expression profile.
- Published
- 2008
- Full Text
- View/download PDF
29. MicroRNA expression in cytogenetically normal acute myeloid leukemia.
- Author
-
Marcucci G, Radmacher MD, Maharry K, Mrózek K, Ruppert AS, Paschka P, Vukosavljevic T, Whitman SP, Baldus CD, Langer C, Liu CG, Carroll AJ, Powell BL, Garzon R, Croce CM, Kolitz JE, Caligiuri MA, Larson RA, and Bloomfield CD
- Subjects
- Adult, Analysis of Variance, DNA-Binding Proteins genetics, DNA-Binding Proteins metabolism, Female, Gene Expression Profiling, Gene Expression Regulation, Leukemic genetics, Genetic Markers, Genetic Predisposition to Disease, Humans, Kaplan-Meier Estimate, Leukemia, Myeloid, Acute pathology, Middle Aged, Mutation, Nuclear Proteins genetics, Nucleophosmin, Oligonucleotide Array Sequence Analysis, Prognosis, Proportional Hazards Models, RNA Probes, Trans-Activators genetics, Trans-Activators metabolism, Transcriptional Regulator ERG, fms-Like Tyrosine Kinase 3 genetics, Gene Expression, Leukemia, Myeloid, Acute genetics, MicroRNAs metabolism, RNA, Neoplasm metabolism
- Abstract
Background: A role of microRNAs in cancer has recently been recognized. However, little is known about the role of microRNAs in acute myeloid leukemia (AML)., Methods: Using microRNA expression profiling, we studied samples of leukemia cells from adults under the age of 60 years who had cytogenetically normal AML and high-risk molecular features--that is, an internal tandem duplication in the fms-related tyrosine kinase 3 gene (FLT3-ITD), a wild-type nucleophosmin (NPM1), or both. A microRNA signature that was associated with event-free survival was derived from a training group of 64 patients and tested in a validation group of 55 patients. For the latter, a microRNA compound covariate predictor (called a microRNA summary value) was computed on the basis of weighted levels of the microRNAs forming the outcome signature., Results: Of 305 microRNA probes, 12 (including 5 representing microRNA-181 family members) were associated with event-free survival in the training group (P<0.005). In the validation group, the microRNA summary value was inversely associated with event-free survival (P=0.03). In multivariable analysis, the microRNA summary value remained associated with event-free survival (P=0.04) after adjustment for the allelic ratio of FLT3-ITD to wild-type FLT3 and for the white-cell count. Using results of gene-expression microarray analysis, we found that expression levels of the microRNA-181 family were inversely correlated with expression levels of predicted target genes encoding proteins involved in pathways of innate immunity mediated by toll-like receptors and interleukin-1beta., Conclusions: A microRNA signature in molecularly defined, high-risk, cytogenetically normal AML is associated with the clinical outcome and with target genes encoding proteins involved in specific innate-immunity pathways., (Copyright 2008 Massachusetts Medical Society.)
- Published
- 2008
- Full Text
- View/download PDF
30. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.
- Author
-
Whitman SP, Ruppert AS, Radmacher MD, Mrózek K, Paschka P, Langer C, Baldus CD, Wen J, Racke F, Powell BL, Kolitz JE, Larson RA, Caligiuri MA, Marcucci G, and Bloomfield CD
- Subjects
- Adult, Aspartic Acid genetics, Aspartic Acid metabolism, Cytogenetics, Disease-Free Survival, Female, Humans, Isoleucine genetics, Isoleucine metabolism, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute therapy, Male, Middle Aged, Mutation genetics, Nucleophosmin, Prognosis, Treatment Outcome, fms-Like Tyrosine Kinase 3 genetics, Gene Expression Regulation, Leukemic genetics, Leukemia, Myeloid, Acute enzymology, Leukemia, Myeloid, Acute pathology, fms-Like Tyrosine Kinase 3 metabolism
- Abstract
The prognostic relevance of FLT3 D835/I836 mutations (FLT3-TKD) in cytogenetically normal acute myeloid leukemia (CN-AML) remains to be established. After excluding patients with FLT3 internal tandem duplications, we compared treatment outcome of 16 de novo CN-AML patients with FLT3-TKD with that of 123 patients with wild-type FLT3 (FLT3-WT), less than 60 years of age and similarly treated on Cancer and Leukemia Group B protocols. All FLT3-TKD(+) patients and 85% of FLT3-WT patients achieved a complete remission (P = .13). Disease-free survival (DFS) of FLT3-TKD(+) patients was worse than DFS of FLT3-WT patients (P = .01; estimated 3-year DFS rates, 31% vs 60%, respectively). In a multivariable analysis, FLT3-TKD was associated with worse DFS (P = .02) independent of NPM1 status and percentage of bone marrow blasts. To gain further biologic insights, a gene-expression signature differentiating FLT3-TKD(+) from FLT3-WT patients was identified. The signature (333 probe sets) included overexpression of VNN1, C3AR1, PTPN6, and multiple other genes involved in monocarboxylate transport activity, and underexpression of genes involved in signal transduction regulation. These associations with outcome, other prognostic markers, and the elucidated expression signature enhance our understanding of FLT3-TKD-associated biology and may lead to development of novel therapies that improve clinical outcome of CN-AML patients with FLT3-TKD.
- Published
- 2008
- Full Text
- View/download PDF
31. STAT1-dependent and STAT1-independent gene expression in murine immune cells following stimulation with interferon-alpha.
- Author
-
Zimmerer JM, Lesinski GB, Radmacher MD, Ruppert A, and Carson WE 3rd
- Subjects
- Animals, Antineoplastic Agents pharmacology, Gene Expression Regulation, Mice, Mice, Inbred C57BL, Microarray Analysis, Signal Transduction immunology, Spleen immunology, Up-Regulation, Interferon-alpha pharmacology, STAT1 Transcription Factor genetics, STAT1 Transcription Factor metabolism, Spleen cytology, Spleen drug effects
- Abstract
Purpose: The precise molecular targets of interferon-alpha (IFN-alpha) therapy of melanoma are unknown but likely involve signal transducer and activator of transcription 1 (STAT1) signal transduction within host immune effector cells. We hypothesized that microarray analysis could be utilized to identify candidate molecular targets important for mediating the anti-tumor effect of exogenously administered IFN-alpha., Experimental Methods: To identify the STAT1-dependent genes regulated by IFN-alpha, the gene expression profile of splenocytes from wild type (WT) and STAT1(-/-) mice was characterized., Results: This analysis identified 30 genes that required STAT1 signal transduction for optimal expression in response to IFN-alpha (p < 0.001). These genes include granzyme b (Gzmb), interferon regulatory factor 7 (Irf7), Fas death domain-associated protein (Daxx), and lymphocyte antigen 6 complex, locus C (Ly6c). The expression of 20 genes was found to be suppressed in the presence of STAT1 including chemokine ligand 2 (Ccl2), Ccl5, and Ccl7. Nineteen genes were significantly upregulated in murine splenocytes following treatment with IFN-alpha regardless of the presence of STAT1 including CD86, lymphocyte antigen 6 complex, locus A (Ly6a), and Tap binding protein (Tapbp). The expression of representative IFN-responsive genes was confirmed at the transcriptional level by Real Time PCR., Conclusion: This report is the first to demonstrate that STAT1-mediated signal transduction plays a major role in the transcriptional response of murine immune cells to IFNalpha.
- Published
- 2007
- Full Text
- View/download PDF
32. Appropriateness of some resampling-based inference procedures for assessing performance of prognostic classifiers derived from microarray data.
- Author
-
Lusa L, McShane LM, Radmacher MD, Shih JH, Wright GW, and Simon R
- Subjects
- Clinical Trials as Topic, Confidence Intervals, DNA Fingerprinting, Humans, Odds Ratio, Data Interpretation, Statistical, Oligonucleotide Array Sequence Analysis statistics & numerical data
- Abstract
The goal of many gene-expression microarray profiling clinical studies is to develop a multivariate classifier to predict patient disease outcome from a gene-expression profile measured on some biological specimen from the patient. Often some preliminary validation of the predictive power of a profile-based classifier is carried out using the same data set that was used to derive the classifier. Techniques such as cross-validation or bootstrapping can be used in this setting to assess predictive power, and if applied correctly, can result in a less biased estimate of predictive accuracy of a classifier. However, some investigators have attempted to apply standard statistical inference procedures to assess the statistical significance of associations between true and cross-validated predicted outcomes. We demonstrate in this paper that naïve application of standard statistical inference procedures to these measures of association under null situations can result in greatly inflated testing type I error rates. Under alternatives of small to moderate associations, confidence interval coverage probabilities may be too low, although for very large associations coverage probabilities approach their intended values. Our results suggest that caution should be exercised in interpreting some of the claims of exceptional prognostic classifier performance that have been reported in prominent biomedical journals in the past few years., (Copyright (c) 2006 John Wiley & Sons, Ltd.)
- Published
- 2007
- Full Text
- View/download PDF
33. Oxygen limitation modulates pH regulation of catabolism and hydrogenases, multidrug transporters, and envelope composition in Escherichia coli K-12.
- Author
-
Hayes ET, Wilks JC, Sanfilippo P, Yohannes E, Tate DP, Jones BD, Radmacher MD, BonDurant SS, and Slonczewski JL
- Subjects
- Down-Regulation drug effects, Drug Resistance, Multiple, Bacterial physiology, Escherichia coli K12 genetics, Escherichia coli K12 metabolism, Escherichia coli Proteins genetics, Genes, Bacterial genetics, Hydrogen-Ion Concentration, Oxygen metabolism, Up-Regulation drug effects, Carrier Proteins genetics, Escherichia coli K12 cytology, Escherichia coli K12 drug effects, Gene Expression Regulation, Bacterial drug effects, Hydrogenase genetics, Oxygen pharmacology
- Abstract
Background: In Escherichia coli, pH regulates genes for amino-acid and sugar catabolism, electron transport, oxidative stress, periplasmic and envelope proteins. Many pH-dependent genes are co-regulated by anaerobiosis, but the overall intersection of pH stress and oxygen limitation has not been investigated., Results: The pH dependence of gene expression was analyzed in oxygen-limited cultures of E. coli K-12 strain W3110. E. coli K-12 strain W3110 was cultured in closed tubes containing LBK broth buffered at pH 5.7, pH 7.0, and pH 8.5. Affymetrix array hybridization revealed pH-dependent expression of 1,384 genes and 610 intergenic regions. A core group of 251 genes showed pH responses similar to those in a previous study of cultures grown with aeration. The highly acid-induced gene yagU was shown to be required for extreme-acid resistance (survival at pH 2). Acid also up-regulated fimbriae (fimAC), periplasmic chaperones (hdeAB), cyclopropane fatty acid synthase (cfa), and the "constitutive" Na+/H+ antiporter (nhaB). Base up-regulated core genes for maltodextrin transport (lamB, mal), ATP synthase (atp), and DNA repair (recA, mutL). Other genes showed opposite pH responses with or without aeration, for example ETS components (cyo,nuo, sdh) and hydrogenases (hya, hyb, hyc, hyf, hyp). A hypF strain lacking all hydrogenase activity showed loss of extreme-acid resistance. Under oxygen limitation only, acid down-regulated ribosome synthesis (rpl,rpm, rps). Acid up-regulated the catabolism of sugar derivatives whose fermentation minimized acid production (gnd, gnt, srl), and also a cluster of 13 genes in the gadA region. Acid up-regulated drug transporters (mdtEF, mdtL), but down-regulated penicillin-binding proteins (dacACD, mreBC). Intergenic regions containing regulatory sRNAs were up-regulated by acid (ryeA, csrB, gadY, rybC)., Conclusion: pH regulates a core set of genes independently of oxygen, including yagU, fimbriae, periplasmic chaperones, and nhaB. Under oxygen limitation, however, pH regulation is reversed for genes encoding electron transport components and hydrogenases. Extreme-acid resistance requires yagU and hydrogenase production. Ribosome synthesis is down-regulated at low pH under oxygen limitation, possibly due to the restricted energy yield of catabolism. Under oxygen limitation, pH regulates metabolism and transport so as to maximize alternative catabolic options while minimizing acidification or alkalinization of the cytoplasm.
- Published
- 2006
- Full Text
- View/download PDF
34. Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study.
- Author
-
Radmacher MD, Marcucci G, Ruppert AS, Mrózek K, Whitman SP, Vardiman JW, Paschka P, Vukosavljevic T, Baldus CD, Kolitz JE, Caligiuri MA, Larson RA, and Bloomfield CD
- Subjects
- Acute Disease, Adult, Algorithms, Cluster Analysis, Ethnicity, Female, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Humans, Karyotyping, Leukemia, Myeloid mortality, Male, Middle Aged, Prognosis, Survival Analysis, Treatment Outcome, Leukemia, Myeloid genetics, Leukemia, Myeloid therapy
- Abstract
Patients with acute myeloid leukemia (AML) and normal karyotype are classified in an intermediate-risk group, albeit this subset is heterogeneous for clinical outcome. A recent complementary DNA microarray study identified a gene-expression signature that--when used to cluster normal karyotype patients--separated them into 2 prognostically relevant subgroups. We sought the first independent validation of the prognostic value of this signature. Using oligonucleotide microarrays to measure gene expression in samples from uniformly treated adults with karyotypically normal AML, we performed cluster analysis based on the previously identified signature. We also developed a well-defined classification rule using the signature to predict outcome for individual patients. Cluster analysis confirmed the prognostic utility of the signature: patient clusters differed in overall (P = .001) and disease-free (P = .001) survival. The signature-based classifier identified groups with differences in overall (P = .02) and disease-free (P = .05) survival. A strong association of the outcome classifier with the prognostically adverse FLT3 internal tandem duplication (FLT3 ITD) potentially explained the prognostic significance of the signature. However, in the subgroup of patients without FLT3 ITD there was a moderate difference in survival for the classifier-derived groups. Our analysis confirms the applicability of the gene-expression profiling strategy for outcome prediction in cytogenetically normal AML.
- Published
- 2006
- Full Text
- View/download PDF
35. Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces.
- Author
-
Kim J, Bronson CL, Hayton WL, Radmacher MD, Roopenian DC, Robinson JM, and Anderson CL
- Subjects
- Albumins biosynthesis, Algorithms, Animals, Electrophoresis, Polyacrylamide Gel, Enzyme-Linked Immunosorbent Assay, Leucine metabolism, Mice, Mice, Inbred C57BL, Mice, Knockout, Proteins metabolism, Receptors, Fc genetics, Serum Amyloid P-Component biosynthesis, Transferrin biosynthesis, Albumins metabolism, Liver metabolism, Receptors, Fc physiology
- Abstract
It is now understood that the nonclassical major histocompatibility complex-I molecule FcRn binds albumin and retrieves it from an intracellular degradative fate. Whether FcRn in the liver modulates albumin turnover through effects on biosynthesis and production is not known. Thus we quantified the appearance of biosynthetically labeled albumin in plasma after an intravenous bolus injection of [(3)H]leucine in FcRn-deficient mice. The production rates for both albumin (FcRn substrate) and transferrin (nonsubstrate) are increased by approximately 20% in FcRn-deficient mice compared with normal mice, likely compensating for the lowered plasma oncotic pressure caused by hypoalbuminemia in FcRn-deficient mice. Determining the magnitude of FcRn-mediated effects on albumin turnover, we then measured the steady-state plasma concentrations of biosynthetically labeled albumin and transferrin during [(3)H]leucine infusion. The concentration of albumin was approximately 40% lower in FcRn-deficient mice compared with normal mice. Furthermore, the approximately 40% lower plasma albumin concentration in FcRn-deficient mice along with the approximately 20% increase in albumin production indicate, by the mass-balance equation, that albumin degradation in FcRn-deficient mice is twice that of normal mice. These studies of biosynthetically labeled, and thus native, albumin support our previous finding that FcRn protects albumin from degradation. Permitting quantification of the magnitude of FcRn-mediated recycling, they further indicate that FcRn has extraordinary capacity: the amount of albumin saved from degradation by FcRn-mediated recycling is the same as that produced by the liver.
- Published
- 2006
- Full Text
- View/download PDF
36. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study.
- Author
-
Marcucci G, Baldus CD, Ruppert AS, Radmacher MD, Mrózek K, Whitman SP, Kolitz JE, Edwards CG, Vardiman JW, Powell BL, Baer MR, Moore JO, Perrotti D, Caligiuri MA, Carroll AJ, Larson RA, de la Chapelle A, and Bloomfield CD
- Subjects
- Acute Disease, Adolescent, Adult, DNA-Binding Proteins genetics, Expressed Sequence Tags, Female, Humans, Karyotyping, Male, Middle Aged, Prognosis, Reverse Transcriptase Polymerase Chain Reaction, Survival Analysis, Trans-Activators genetics, Transcriptional Regulator ERG, Up-Regulation, DNA-Binding Proteins biosynthesis, Gene Expression Profiling, Leukemia, Myeloid genetics, Leukemia, Myeloid pathology, Trans-Activators biosynthesis
- Abstract
Purpose: To test the prognostic significance of ETS-related gene (ERG) expression in cytogenetically normal primary acute myeloid leukemia (AML)., Patients and Methods: Pretreatment blood samples from 84 cytogenetically normal AML patients aged less than 60 years, who were characterized for BAALC expression, FLT3 internal tandem duplication (ITD), and MLL partial tandem duplication (PTD) and uniformly treated on Cancer and Leukemia Group B 9621 protocol, were analyzed for ERG expression by real-time reverse transcriptase polymerase chain reaction. Patients were divided into quartiles according to ERG levels and were compared for clinical outcome. High-density oligonucleotide arrays were used to identify genes differentially expressed between high and low ERG expressers., Results: With a median follow-up of 5.7 years, patients with the upper 25% of ERG expression values had a worse cumulative incidence of relapse (CIR; P < .001) and overall survival (OS; P = .011) than the remaining patients. In a multivariable analysis, high ERG expression (P < .001) and the presence of MLL PTD (P = .027) predicted worse CIR. With regard to OS, an interaction was observed between expression of ERG and BAALC (P = .013), with ERG overexpression predicting shorter survival only in low BAALC expressers (P = .002). ERG overexpression was an independent prognostic factor even when the unfavorable group of FLT3 ITD patients lacking an FLT3 wild-type allele was included. High ERG expression was associated with upregulation of 112 expressed-sequenced tags and named genes, many of which are involved in cell proliferation, differentiation, and apoptosis., Conclusion: ERG overexpression in AML patients with normal cytogenetics predicts an adverse clinical outcome and seems to be associated with a specific molecular signature.
- Published
- 2005
- Full Text
- View/download PDF
37. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification.
- Author
-
Simon R, Radmacher MD, Dobbin K, and McShane LM
- Subjects
- Cluster Analysis, Confounding Factors, Epidemiologic, DNA, Neoplasm analysis, Diagnosis, Differential, Humans, Predictive Value of Tests, Prognosis, Reproducibility of Results, Research Design, Neoplasms diagnosis, Neoplasms genetics, Oligonucleotide Array Sequence Analysis
- Published
- 2003
- Full Text
- View/download PDF
38. Methods for assessing reproducibility of clustering patterns observed in analyses of microarray data.
- Author
-
McShane LM, Radmacher MD, Freidlin B, Yu R, Li MC, and Simon R
- Subjects
- DNA classification, DNA genetics, Gene Expression Profiling methods, Gene Expression Regulation, Neoplastic genetics, Humans, Male, Melanoma classification, Pattern Recognition, Automated, Prostatic Hyperplasia classification, Prostatic Neoplasms classification, Quality Control, Reference Values, Reproducibility of Results, Sensitivity and Specificity, Sequence Analysis, DNA methods, Stochastic Processes, Cluster Analysis, Melanoma genetics, Oligonucleotide Array Sequence Analysis methods, Prostatic Hyperplasia genetics, Prostatic Neoplasms genetics, Sequence Alignment methods
- Abstract
Motivation: Recent technological advances such as cDNA microarray technology have made it possible to simultaneously interrogate thousands of genes in a biological specimen. A cDNA microarray experiment produces a gene expression 'profile'. Often interest lies in discovering novel subgroupings, or 'clusters', of specimens based on their profiles, for example identification of new tumor taxonomies. Cluster analysis techniques such as hierarchical clustering and self-organizing maps have frequently been used for investigating structure in microarray data. However, clustering algorithms always detect clusters, even on random data, and it is easy to misinterpret the results without some objective measure of the reproducibility of the clusters., Results: We present statistical methods for testing for overall clustering of gene expression profiles, and we define easily interpretable measures of cluster-specific reproducibility that facilitate understanding of the clustering structure. We apply these methods to elucidate structure in cDNA microarray gene expression profiles obtained on melanoma tumors and on prostate specimens.
- Published
- 2002
- Full Text
- View/download PDF
39. Design of studies using DNA microarrays.
- Author
-
Simon R, Radmacher MD, and Dobbin K
- Subjects
- Computational Biology, DNA Replication, Epidemiologic Methods, Gene Expression Profiling methods, Models, Genetic, Research Design, Oligonucleotide Array Sequence Analysis
- Abstract
DNA microarrays are assays that simultaneously provide information about expression levels of thousands of genes and are consequently finding wide use in biomedical research. In order to control the many sources of variation and the many opportunities for misanalysis, DNA microarray studies require careful planning. Different studies have different objectives, and important aspects of design and analysis strategy differ for different types of studies. We review several types of objectives of studies using DNA microarrays and address issues such as selection of samples, levels of replication needed, allocation of samples to dyes and arrays, sample size considerations, and analysis strategies., (Copyright 2002 Wiley-Liss, Inc.)
- Published
- 2002
- Full Text
- View/download PDF
40. A paradigm for class prediction using gene expression profiles.
- Author
-
Radmacher MD, McShane LM, and Simon R
- Subjects
- Algorithms, Breast Neoplasms pathology, Computational Biology, Female, Gene Expression Regulation, Neoplastic genetics, Genotype, Germ-Line Mutation, Humans, BRCA1 Protein genetics, BRCA2 Protein genetics, Breast Neoplasms classification, Breast Neoplasms genetics, Gene Expression Profiling, Oligonucleotide Array Sequence Analysis
- Abstract
We propose a general framework for prediction of predefined tumor classes using gene expression profiles from microarray experiments. The framework consists of 1) evaluating the appropriateness of class prediction for the given data set, 2) selecting the prediction method, 3) performing cross-validated class prediction, and 4) assessing the significance of prediction results by permutation testing. We describe an application of the prediction paradigm to gene expression profiles from human breast cancers, with specimens classified as positive or negative for BRCA1 mutations and also for BRCA2 mutations. In both cases, the accuracy of class prediction was statistically significant when compared to the accuracy of prediction expected by chance. The framework proposed here for the application of class prediction is designed to reduce the occurrence of spurious findings, a legitimate concern for high-dimensional microarray data. The prediction paradigm will serve as a good framework for comparing different prediction methods and may accelerate the development of molecular classifiers that are clinically useful.
- Published
- 2002
- Full Text
- View/download PDF
41. Graph models of oncogenesis with an application to melanoma.
- Author
-
Radmacher MD, Simon R, Desper R, Taetle R, Schäffer AA, and Nelson MA
- Subjects
- Cytogenetic Analysis, Disease Progression, Humans, Chromosome Breakage, Melanoma genetics, Models, Genetic, Models, Statistical
- Abstract
We describe several analytical techniques for use in developing genetic models of oncogenesis including: methods for the selection of important genetic events, construction of graph models (including distance-based trees, branching trees, contingency trees and directed acyclic graph models) from these events and methods for interpretation of the resulting models. The models can be used to make predictions about: which genetic events tend to occur early, which events tend to occur together and the likely order of events. Unlike simple path models of oncogenesis, our models allow dependencies to exist between specific genetic changes and allow for multiple, divergent paths in tumor progression. A variety of genetic events can be used with the graph models including chromosome breaks, losses or gains of large DNA regions, small mutations and changes in methylation. As an application of the techniques, we use a recently published cytogenetic analysis of 206 melanoma cases [Nelson et al. (2000), Cancer Genet. Cytogenet.122, 101-109] to derive graph models for chromosome breaks in melanoma. Among our predictions are: (1) breaks in 6q1 and 1q1 are early events, with 6q1 preferentially occurring first and increasing the probability of a break in 1q1 and (2) breaks in the two sets [1p1, 1p2, 9q1] and [1q1, 7p2, 9p2] tend to occur together. This study illustrates that the application of graph models to genetic data from tumor sets provide new information on the interrelationships among genetic changes during tumor progression., (Copyright 2001 Academic Press.)
- Published
- 2001
- Full Text
- View/download PDF
42. Waiting times to appearance and dominance of advantageous mutants: estimation based on the likelihood.
- Author
-
Radmacher MD and Kepler TB
- Subjects
- Animals, Antibody Formation genetics, Antibody Formation immunology, B-Lymphocytes immunology, Computer Simulation, Genes, Dominant, Likelihood Functions, Monte Carlo Method, Mutation immunology, Nitrophenols immunology, Phenylacetates, Stochastic Processes, Vertebrates immunology, Germinal Center immunology, Models, Genetic, Mutation genetics, Selection, Genetic, Vertebrates genetics
- Abstract
The germinal center reaction (GCR) of vertebrate immunity provides a remarkable example of evolutionary succession, in which an advantageous phenotype arises as a spontaneous mutation from the parental type and eventually displaces the parental type altogether. In the case of the immune response to the hapten (4-hydroxy-3-nitrophenyl)acetyl (NP), as with several other designed immunogens, the process is dominated by a single key mutation, which greatly simplifies the modeling of and analysis of data. We developed a two-stage model of this process in which the primary stage represents the appearance and establishment of the mutant population as a stochastic process while the second stage represents the growth and dominance of the clone as a deterministic process, conditional on its time of establishment from stage one. We applied this model to the analysis of population samples from several germinal center (GC) reactions and used maximum-likelihood methods to estimate the waiting times to arrival and to dominance of the mutant clone. We determined the sampling properties of the maximum-likelihood estimates using Monte Carlo methods and compared them to their asymptotic distributions. The methods we present here are well-suited for use in the analysis of other systems, such as tumor growth and the experimental evolution of bacteria.
- Published
- 2001
- Full Text
- View/download PDF
43. Chromosome abnormalities in malignant melanoma: clinical significance of nonrandom chromosome abnormalities in 206 cases.
- Author
-
Nelson MA, Radmacher MD, Simon R, Aickin M, Yang J, Panda L, Emerson J, Roe D, Adair L, Thompson F, Bangert J, Leong SP, Taetle R, Salmon S, and Trent J
- Subjects
- DNA, Neoplasm genetics, Female, Humans, Karyotyping, Male, Melanoma pathology, Middle Aged, Ploidies, Survival Analysis, Chromosome Aberrations, Chromosome Disorders, Melanoma genetics
- Abstract
We report the cytogenetic abnormalities from a series of 206 primary malignant melanoma specimens referred to a single institution. A total of 169 out of 206 unique cases had chromosome breakpoints. A previously described statistical method was used to detect nonrandom distribution of chromosome breakpoints at the level of chromosome regions. Nonrandom occurrence of chromosome breakpoints (indicating that the observed number of breaks significantly exceeded the expected number of breaks) was detected in 28 regions, suggesting a hierarchy of genetic abnormalities in melanoma. Clinical variables and tumor characteristics were analyzed for associations with the presence of any nonrandom chromosome breakpoints; with individual, nonrandomly involved chromosome regions; and with paired, nonrandomly involved chromosome regions. No nonrandomly involved chromosome regions or pairs of regions appeared to significantly affect survival. These results identify recurring, nonrandom chromosome abnormalities in malignant melanoma. These results suggest that recurring, nonrandom chromosome alterations play a key role in the etiology and/or progression of malignant melanoma and identify targets within the genome for molecular genetic studies.
- Published
- 2000
- Full Text
- View/download PDF
44. RESPONSE: re: estimation of Tamoxifen's efficacy for preventing the formation and growth of breast tumors
- Author
-
Radmacher MD and Simon R
- Published
- 2000
- Full Text
- View/download PDF
45. Estimation of tamoxifen's efficacy for preventing the formation and growth of breast tumors.
- Author
-
Radmacher MD and Simon R
- Subjects
- Adult, Aged, Female, Humans, Incidence, Male, Middle Aged, Neoplasms, Unknown Primary drug therapy, Treatment Outcome, Anticarcinogenic Agents therapeutic use, Antineoplastic Agents, Hormonal therapeutic use, Breast Neoplasms drug therapy, Breast Neoplasms prevention & control, Estrogen Receptor Modulators therapeutic use, Tamoxifen therapeutic use
- Abstract
Background: Several randomized clinical trials have tested the hypothesis that tamoxifen is effective in preventing breast cancer. The largest such trial, the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention Trial (BCPT), reported a 49% reduction in risk of invasive breast cancer for the tamoxifen group. However, it is unclear whether the effect of tamoxifen in this trial was mainly due to prevention of newly forming tumors or to treatment of occult disease., Methods: We used various tumor growth models (i.e., exponential and Gompertzian [growth limited by tumor size]) and a computer simulation to approximate the percentage of detected tumors that were initiated after study entry. Maximum likelihood techniques were then used to estimate separately the efficacy of tamoxifen in treating occult disease and in preventing the formation and growth of new tumors., Results: Under the assumptions of most of the growth models, the trial was sufficiently long for substantial numbers of new tumors to form, grow, and be detected during the trial. With the Gompertzian model and all available incidence data from the BCPT, it was estimated that 60% (95% confidence interval [CI] = 40%-80%) fewer new tumors were detected in the tamoxifen group than in the placebo group. Likewise, 35% (95% CI = 6%-63%) fewer occult tumors were detected in the tamoxifen group. With this model, the estimated incidence rate of invasive breast cancer among women in the placebo group of the BCPT was 7.7 (95% CI = 6.6-8.9) per 1000 women per year. Similar results were obtained with three exponential tumor growth models., Conclusions: These results support the concept that tamoxifen reduced cancer incidence in the BCPT through both treatment of occult disease and prevention of new tumor formation and growth. However, data from prevention trials may never be sufficient to completely distinguish prevention of new tumor formation from treatment of occult disease.
- Published
- 2000
- Full Text
- View/download PDF
46. Predicted and inferred waiting times for key mutations in the germinal centre reaction: evidence for stochasticity in selection.
- Author
-
Radmacher MD, Kelsoe G, and Kepler TB
- Subjects
- Animals, Cell Differentiation, Humans, Stochastic Processes, Time Factors, Germinal Center, Mutation
- Abstract
The germinal centre reaction (GCR) is a fundamental component of the immune response to T-dependent antigens, during which the immunoglobulin (Ig) genes of B cells experience somatic hypermutation and selection. A maximum-likelihood method on DNA sequence data from 16 individual germinal centres was used to infer that the waiting time for position 33 key (high-affinity) mutations in the anti-(4-hydroxy-3-nitrophenyl) acetyl (NP) response is 8.3 days. This is in marked contrast to the prediction of a key mutant each generation (waiting time about 1/3 day) obtained from a simple model and parameters available in the literature. This disagreement is resolved in part by the finding that the targeted base occurs in a cold spot for hypermutation, raising the predicted waiting time to 2.3 days, although this value remains significantly lower than that inferred from the sequence data. It is proposed that the remaining disparity is attributable to some further stochastic process in the GCR: many early key mutations arise but fail to 'take root' within the GC, either due to emigration or failure of cognate T cell/B cell interaction. Furthermore, it is argued that the frequency with which position 33 mutations are found in secondary responses to NP indicates the presence of selection after the GCR.
- Published
- 1998
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.